Idiopathic pulmonary fibrosis market will grow from $907 million in 2015 to $3.2 billion by 2025
![](/46/pdcnewsitem/04/13/91/GDnewlogo.jpg)
Growth will primarily be driven by increased use of expensive therapies, a rise in diagnosed prevalent cases of IPF, and the launch of two novel therapies, says GlobalData.
The idiopathic pulmonary fibrosis (IPF) market will rise substantially from just over $900 million in 2015 to $3.2 billion by 2025, representing an impressive compound annual growth rate of 13.6%, according to research and consulting firm GlobalData.
The company’s latest report — OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecast to 2025 — states that such growth, which will occur across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will primarily be driven by the increased use of expensive therapies, the anticipated launches of two novel therapies, FibroGen’s FG-3019 and Promedior’s PRM-151, and a rise in diagnosed prevalent cases of the disease.
Matthew Thaxter, MSc, GlobalData’s Analyst covering Immunology, explains: “Currently, the IPF market is largely under-penetrated, with only two approved treatments across the 7MM. However, pharmaceutical companies are increasingly starting to view the IPF drug market as one with commercial potential.
“IPF has an attractive patient population size, with almost 108,000 diagnosed prevalent cases in the 7MM, and the opportunity to attain orphan drug status, potentially allowing a faster and more cost-efficient research and development program.”
As the IPF market has been largely neglected to date, the level of unmet needs within the indication remains high, both environmentally – in terms of treatment cost, patient awareness, and physician education – and clinically. Indeed, the foremost unmet is the lack of an efficacious therapy which is capable of halting the progression of the disease.
Thaxter explains: “The two currently approved products – Roche’s Esbriet and Boehringer Ingelheim’s Ofev – are not capable of meeting this particular unmet need, as they serve merely to slow the decline in patients’ lung function. Promising Phase II drugs are set to be developed and approved over the forecast period to 2025, and the IPF market will evolve, due to the improvements offered by these newer drugs.
“There will be continued effort on behalf of both pharmaceutical companies and other industry stakeholders to increase the awareness of IPF among patients and physicians alike, thereby improving diagnosis and treatment rates. Excitingly, following the approvals of FibroGen’s FG-3019 and Promedior’s PRM-151 into the IPF therapeutic market, anticipated in 2021 and 2023, respectively, the unmet need for a therapy that can reverse or stabilize fibrosis will have been met.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance